BioSight
Companies
Nanobiotix S.A. logo

NBTX

NASDAQPARIS, I0
Nanobiotix S.A.

Nanobiotix S.A. is a clinical-stage biotechnology company developing NBTXR3 (also known as JNJ-1900), a product candidate in oncology that is being co-developed with Janssen Pharmaceutica NV under a license agreement dated July 7, 2023. The company was incorporated in France in 2003 and trades on Euronext Paris and Nasdaq under the ticker NBTX.

Price history not yet available for NBTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar